Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1988 2
1989 1
1990 2
1991 1
2000 1
2001 1
2002 3
2003 1
2004 1
2005 2
2006 2
2007 3
2008 1
2009 1
2010 1
2011 2
2012 1
2013 2
2014 1
2015 1
2019 1
2020 3
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
Peled N, Roisman LC, Levison E, Dudnik J, Chernomordikov E, Heching N, Dudnik E, Keren-Rosenberg S, Nechushtan H, Salhab A, Hershkovitz D, Tsuriel S, Hannes V, Rotem O, Lazarev I, Lichtenberg R, Granot IS, Krayim B, Shalata W, Levin D, Krutman Y, Allen AM, Blumenfeld P, Lavrenkov K, Kian W. Peled N, et al. Among authors: lavrenkov k. Int J Radiat Oncol Biol Phys. 2023 Sep 1;117(1):105-114. doi: 10.1016/j.ijrobp.2023.03.042. Epub 2023 Mar 15. Int J Radiat Oncol Biol Phys. 2023. PMID: 36925073 Clinical Trial.
Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study.
Kian W, Zemel M, Kestenbaum EH, Rouvinov K, Alguayn W, Levitas D, Ievko A, Michlin R, Abod MA, Massalha I, Chernomordikov E, Sharb AA, Shalata W, Levison E, Roisman LC, Lavrenkov K, Peled N, Nesher L, Yakobson A. Kian W, et al. Among authors: lavrenkov k. Medicine (Baltimore). 2022 Jan 14;101(2):e28561. doi: 10.1097/MD.0000000000028561. Medicine (Baltimore). 2022. PMID: 35029223 Free PMC article.
Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma.
Kian W, Roisman LC, Goldstein IM, Abo-Quider A, Samueli B, Wallach N, Alguayn F, Shalata W, Levitas D, Belochitski O, Levin D, Fenig E, Lavrenkov K, Tokar M, Peled N, Yakobson A. Kian W, et al. Among authors: lavrenkov k. JCO Precis Oncol. 2020 Apr 30;4:PO.19.00264. doi: 10.1200/PO.19.00264. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923880 Free PMC article. No abstract available.
Hemoglobin Levels and Red Blood Cells Distribution Width Highlights Glioblastoma Patients Subgroup With Improved Median Overall Survival.
Kaisman-Elbaz T, Elbaz Y, Merkin V, Dym L, Noy A, Atar-Vardi M, Bari R, Turiel S, Alt A, Zamed T, Eskira Y, Lavrenkov K, Kezerle Y, Dyomin V, Melamed I. Kaisman-Elbaz T, et al. Among authors: lavrenkov k. Front Oncol. 2020 Apr 17;10:432. doi: 10.3389/fonc.2020.00432. eCollection 2020. Front Oncol. 2020. PMID: 32426265 Free PMC article.
The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
Brenner A, Friger M, Geffen DB, Kaisman-Elbaz T, Lavrenkov K. Brenner A, et al. Among authors: lavrenkov k. Oncology. 2019;97(5):255-263. doi: 10.1159/000500926. Epub 2019 Jul 9. Oncology. 2019. PMID: 31288238
38 results